Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyPremera Bluecross Psoriasis Coverage Update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedPremera BluecrossPolicy 5.01.629

    Pharmacologic Treatment of Psoriasis

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.629 alerts

    Get alerted when Policy 5.01.629 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and site-of-service criteria for systemic, biologic, and infusion/injectable pharmacologic treatments for psoriasis for Premera Bluecross members; intended for providers seeking coverage requirements and prior authorization guidance.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacologic Treatment of Psoriasis
    Policy CodePolicy 5.01.629
    Change TypeMaterial updates to age/weight thresholds and preferred alternatives
    Effective DateAug 1, 2026
    Last ReviewJul 27, 2026
    Next Review Date
    Key ActionObtain prior authorization documenting age, disease extent (commonly ≥10% BSA), prior trial/failure of specified systemic agents, and dermatologist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Otezla XR (apremilast extended release) for the treatment of psoriasis in individuals aged 6 years and older and weighing at least 50 kg.

    Added Otezla XR to list of preferred alternatives for multiple biologics (Bimzelx, Siliq, Cosentyx, Cimzia, Ilumya).

    Updated coverage criteria for Tremfya (guselkumab) to include individuals weighing at least 40 kg.

    Updated coverage criteria for Tremfya (guselkumab) to include individuals weighing at least 40 kg and updated age requirement to 6 years or older in a later revision.

    Added coverage criteria for Icotyde (icotrokinra) for treatment of psoriasis in individuals aged 12 years or older and weighing at least 40 kg.

    Added coverage criteria for Spesolimab (Spevigo) IV and SC for generalized pustular psoriasis and included safety data from GPP and PPP trials.

    Added coverage criteria for Otezla XR to preferred alternative lists for multiple biologics and updated Skyrizi age requirement to 6 years or older.

    >=6 yrsMinimum age added
    >=50 kgOtezla XR weight
    >=40 kgTremfya weight
    1 systemicPrior therapy required
    90 daysInitial hospital outpatient coverage
    Q5164New HCPCS

    Coverage Criteria and Medical Necessity

    Site of Service (SOS) Medical Necessity

    Covered when ALL of the following are met (site-of-service logic):

    SOS general

    • Preferred sites: Physician's office OR Infusion center OR Home infusion OR Hospital-based outpatient setting

      Preferred medically necessary sites (chunks 2-3)

    • Initial-course coverage: Hospital-based outpatient site is considered medically necessary for first 90 days for initial course or re-initiation after >=6 months (not when standard dosing interval is >=6 months)90 days

      chunk 2

    • Exceptions requiring hospital setting:
    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacologic Treatment of Psoriasis
    Policy CodePolicy 5.01.629
    Change TypeMaterial updates to age/weight thresholds and preferred alternatives
    Effective DateAug 1, 2026
    Last ReviewJul 27, 2026
    Next Review Date
    Key ActionObtain prior authorization documenting age, disease extent (commonly ≥10% BSA), prior trial/failure of specified systemic agents, and dermatologist involvement.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCoding, Codes and Key Clinical ThresholdsActions Required by Ordering/Prescribing ProvidersBackground and Safety EvidenceDefinitions and Clinical Terms
    No outpatient infusion center within 50 miles and no contracted home infusion agency OR hospital is only place offering the drug
    50 miles

    chunk 2

  1. High-risk clinical conditions: Known cardiac condition, unstable renal function, difficult vascular access, acute mental status changes affecting safety, or history of severe adverse drug reactions/anaphylaxis

    chunk 3

  2. CRS requirement: If cytokine release syndrome (CRS) grade 3 or 4 (temperature >=38°C AND hypotension requiring >=1 vasopressor AND hypoxia requiring high-flow oxygen or positive pressure) AND individual will be admitted to inpatient settingCRS grade 3 or 4

    chunk 3

  3. Agent-specific Medical Necessity for Plaque Psoriasis

    Covered when ALL of the following are met (common agent-level logic repeated across agents unless otherwise noted):

    Common criteria: 1) Age meets agent-specific threshold; 2) Diagnosis of chronic plaque psoriasis; 3) Disease involving >=10% BSA (exceptions allowed for recalcitrant facial, genital, or pustular hand/foot involvement); 4) History of adequate trial and treatment failure with at least 1 approved systemic therapy (methotrexate, cyclosporine, acitretin, or PUVA) unless contraindicated or not tolerated; 5) Medication prescribed by or in consultation with a dermatologist>=10% BSA; prior trial of >=1 systemic agent

    chunks 6-16

    Agent-specific age exceptions and variants: Some agents list different minimum ages (e.g., Enbrel age >=4 yrs, many biologics age >=6 yrs, some oral agents age >=18 yrs)agent-specific

    chunks 6,8,9,11,12

    Agents allowed as emergent therapy: Certain infliximab products (Avsola, Inflectra, Janssen infliximab) may be used emergently for severe pustular, exfoliative, or inflammatory psoriasis without prior first-line drug failureemergent severe disease

    chunk 8

    Second-line and step requirements: Some second-line agents require documented inadequate response or intolerance to specified first-line agents; Siliq requires intolerance or inadequate response to 2 listed agents prior to approvalprior failures to specified agents

    chunks 13-16

    Step Therapy / Line-of-Therapy Groupings

    Agents are grouped into first-line and second-line tiers; approval may require prior failure of agents in earlier tiers.

    First-line groups: Includes TNF-α antagonists, IL-17 inhibitors, IL-23 inhibitors, TYK2 inhibitors, PDE-4 inhibitors with specific agents listed under each class (see policy for agent lists)

    chunks 4-6

    Second-line groups: Includes specified second-line IL-23, IL-17, and TNF-α agents (e.g., certain adalimumab products and listed IL-23/IL-17 agents); many second-line approvals require prior failure of first-line agentsprior failure per policy

    chunks 4-5,18

    Second-line TNF-α antagonists (adalimumab products)

    Covered when ALL of the following are met

    Age: Individual is aged 18 years or older18 years

    chunk 18

    Diagnosis: Chronic plaque psoriasis involving at least 10% BSA>=10% BSA (exceptions allowed)

    Exceptions: extensive recalcitrant facial involvement OR pustular involvement of hands/feet OR genital involvement interfering with sexual function

    Prior therapy: History of adequate trial and treatment failure with at least 1 approved systemic therapy (e.g., methotrexate, cyclosporine, acitretin, PUVA) unless contraindicated or not toleratedat least 1 systemic agent

    AND inadequate response or intolerance to specified adalimumab agents listed in policy

    Prescriber: Medication prescribed by or in consultation with a dermatologist

    chunk 18

    Cimzia (certolizumab pegol) criteria

    Covered when ALL of the following are met

    Age: Individual is aged 18 years or older18 years

    chunk 20

    Diagnosis: Chronic plaque psoriasis involving at least 10% BSA>=10% BSA (exceptions allowed)

    Exceptions: facial, pustular hands/feet, genital interference

    Prior systemic therapy: History of adequate trial and treatment failure with at least 1 approved systemic therapy unless contraindicated or not tolerated

    chunk 20

    Step biologic/oral agents: Inadequate response or intolerance to 2 of listed agents (e.g., Enbrel, adalimumab products with NDCs starting 00597, Otezla/Otezla XR, Skyrizi, Sotyktu, Stelara, Taltz, Tremfya)

    chunk 20

    Prescriber: Medication prescribed by or in consultation with a dermatologist

    chunk 20

    Infliximab products (Remicade, Janssen unbranded, Renflexis)

    Covered when ALL of the following are met (moderate to severe plaque psoriasis)

    Age: Individual is aged 18 years or older18 years

    chunk 21

    Diagnosis: Chronic plaque psoriasis involving at least 10% BSA>=10% BSA (exceptions allowed)

    Exceptions: facial, pustular hands/feet, genital interference

    Prior therapy: History of adequate trial and treatment failure with at least 1 approved systemic therapy unless contraindicated or not tolerated

    For Renflexis: documented trial and treatment failure with Avsola and Inflectra required for individuals not previously treated with requested therapy

    Prescriber: Medication prescribed by or in consultation with a dermatologist

    chunk 21

    Ustekinumab (IL-12/23) and IL-23 inhibitor class and Ilumya/Icotyde

    Covered when ALL of the following are met (agent-specific age thresholds apply)

    Age: Ustekinumab class agents: aged 6 years or older where indicated; Icotyde: aged 12 years or older and weighs at least 40 kg; Ilumya: aged 18 years or olderagent-specific

    chunks 23-24

    Diagnosis: Chronic plaque psoriasis involving at least 10% BSA>=10% BSA (exceptions allowed)

    Exceptions: facial, pustular hands/feet, genital interference

    Prior therapy: History of adequate trial and treatment failure with at least 1 approved systemic therapy unless contraindicated or not tolerated

    Plus documented inadequate response or intolerance to specified comparator biologics or agents as required by drug-specific criteria

    Dose/quantity limits: For some oral agents the dose is limited to 200 mg daily and quantity limited to 30 tablets per 30 days (where specified)

    chunk 25

    Prescriber: Medication prescribed by or in consultation with a dermatologist

    chunk 23

    Emergent use of infliximab for severe psoriasis variants

    Covered when ANY of the following severe conditions are present (emergent treatment)

    Severe disease variants: Severe pustular, exfoliative, or inflammatory psoriasis

    May be eligible for infliximab without prior use or failure of first-line agents

    Coverage criteria and evidence-linked thresholds

    Covered when ALL specified program-specific benefit and clinical criteria are met (examples and trial-defined eligibility shown in evidence):

    Benefit routing and management: Specific agents are managed under the medical benefit (e.g., infliximab products) or both medical and pharmacy benefits (listed agents) — coverage requires routing to the appropriate benefit and meeting that benefit's prior authorization criteria.

    chunks 36-37

    Otezla XR pediatric coverage: Otezla XR (apremilast XR) is covered for treatment of psoriasis in individuals aged >=6 years and weighing >=50 kg when benefit criteria are met.age >=6 years; weight >=50 kg

    2026 Update; chunk 55

    Tremfya weight requirement: Tremfya (guselkumab) coverage criteria updated to require individuals to weigh at least 40 kg.weight >=40 kg

    chunk 55

    Pustular psoriasis (GPP) acute flare therapy: Clinical trial criteria used in evidence (e.g., GPPGA pustulation subscore >=2 and >=5% BSA) illustrate severity thresholds for acute GPP flare treatment decisions; spesolimab showed benefit for GPP flare endpoints (GPPGA pustulation subscore 0 at Week 1).GPPGA pustulation subscore >=2; BSA >=5% for trial inclusion

    chunks 51-52

    General agent coverage with age/weight and step therapy requirements

    Covered when all plan-specific medical necessity and step-therapy criteria are met as detailed in the policy sections for each agent.

    agent-specific coverage: Agent is FDA-approved for the indication OR addressed in policy; individual meets age and weight thresholds where specified (e.g., Otezla XR >=6 years and >=50 kg; Tremfya >=6 years and >=40 kg; Icotyde >=12 years and >=40 kg).see agent-specific thresholds in policy

    Also requires adherence to step therapy/preferred product sequencing and prior authorization rules where applicable (chunks 55,66,71)

    Spevigo (spesolimab) coverage and safety

    Spesolimab (Spevigo) — pustular psoriasis coverage notes

    Spevigo for GPP flares: Coverage supports use for generalized pustular psoriasis (GPP) flares with noted trial safety profile; monitoring for serious adverse events including DRESS is indicated.N/A

    Trial data: Grade 3/4 AEs <10% in GPP; SAEs 6% at Week 1 and 12% at Week 12; no deaths reported (chunk 54)

    For Alaska fully-insured members the site-of-service medical necessity criteria do not apply. For those members, only the infusion/injection drug Medical Necessity criteria apply; check the member's plan booklet or ID card and refer to the applicable infusion and injection drug medical necessity policy for coverage determinations.

    This policy does not address intravenous (IV) and injectable therapy services for individuals who are receiving inpatient services; inpatient administration is outside the scope of the site-of-service provisions in this document.

    All uses of the drugs listed for conditions that are approved in their product labeling but that do not meet the specific drug-level coverage criteria in this policy are considered not medically necessary.

    Use of agents listed in this policy in combination with one another, or use for conditions not described in this policy or related medical policies, is considered investigational and therefore not medically necessary.

    The manufacturer is not pursuing FDA approval of spesolimab for palmoplantar pustulosis (PPP). A Phase 2a PPP trial did not meet the primary endpoint (no difference in PPPASI-50 at Week 16 versus placebo), and therefore use of spesolimab for PPP is not supported by the pivotal evidence cited in this policy.

    Topical agents and several other drugs were migrated out of this policy into policy 5.01.652 (Miscellaneous Pharmacologic Treatments of Psoriasis). Examples moved include Vtama (tapinarof), Zoryve cream (roflumilast), Duobrii, Enstilar, Taclonex, Wynzora, brand calcipotriene formulations, Dovonex, Sorilux, Vectical, Soriatane, and Spevigo (spesolimab-sbzo).

    Infusion and injectable therapy services administered at sites that do not meet the site-of-service criteria in this policy are considered not medically necessary and may be denied; additionally, IV-administered drugs described in this policy must be billed through the medical benefit (not pharmacy).

    All other uses of the drugs listed in this policy that do not meet the drug-specific coverage criteria are considered not medically necessary.

    In the PPP trial, spesolimab did not demonstrate a statistically significant difference versus placebo for the primary endpoint of PPPASI-50 at Week 16; accordingly, use of spesolimab for PPP would be considered unsupported by the pivotal evidence presented and is not covered under this policy segment.

    Site-of-service medical necessity criteria and pharmacy benefit exclusions apply depending on the member's plan and formulary. Coverage rules and site-of-service review may not apply to certain custom formularies or to some Medicare Advantage plans; confirm plan-specific applicability before requesting services.

    Coding, Codes and Key Clinical Thresholds

    NDC identifiers referenced in policyNDC
    NDCs starting with 82009Adalimumab-adbm [NDCs starting with 82009] (listed in policy)
    NDCs starting with 00597Adalimumab-adbm (specific NDC block noted in policy)
    Selected J-codes (documented in policy)HCPCS
    J0139Injection, adalimumab, 1 mg
    J0717Injection, certolizumab pegol (Cimzia), 1 mg
    J1628Injection, guselkumab (Tremfya), 1 mg (note: J1628 also referenced for etanercept entries in policy)
    J1745Injection, infliximab, excludes biosimilar (Remicade or Janssen unbranded), 10 mg
    J3245Injection, tildrakizumab (Ilumya), 1 mg
    J3357Injection, ustekinumab, subcutaneous injection (Stelara), 1 mg
    J3590Unclassified biologics (use only to report listed unclassified biologics)
    HCPCS / Q-code list (biosimilars and biologics)HCPCS
    Q5098Injection, ustekinumab-srlf (Imuldosa), biosimilar, 1 mg
    Q5099Injection, ustekinumab-stba (Steqeyma), biosimilar, 1 mg
    Q5100Injection, ustekinumab-kfce (Yesintek), biosimilar, 1 mg
    Q5103Injection, infliximab-dyyb (Inflectra), biosimilar, 10 mg
    Q5104Injection, infliximab-abda (Renflexis), biosimilar, 10 mg
    Q5121Injection, infliximab-axxq (Avsola), biosimilar, 10 mg
    Q5137Injection, ustekinumab-auub (Wezlana), biosimilar, subcutaneous, 1 mg
    Q5140Injection, adalimumab-fkjp, biosimilar, 1 mg
    Q5141Injection, adalimumab-aaty, biosimilar, 1 mg
    Q5142Injection, adalimumab-ryvk, biosimilar, 1 mg
    1–10 of 17
    1/2
    Agents listed in policy (by trade name and biosimilar identifiers)mixed
    Avsolainfliximab-axxq
    Inflectrainfliximab-dyyb
    Infliximab (Janssen)unbranded infliximab
    Remicadeinfliximab
    Renflexisinfliximab-abda
    Abriladaadalimumab-afzb
    adalimumab-adbmCyltezo unbranded
    adalimumab-aacfIdacio unbranded
    adalimumab-adazHyrimoz unbranded
    adalimumab-bwwdbiosimilar adalimumab
    1–10 of 35
    1/4
    HCPCS/Other codes mentionedHCPCS
    J3590Unspecified biologics (parentheticals used in policy for some agents)
    Q5164HCPCS code added for Icotyde effective July 1, 2026
    Q5098HCPCS code (Imuldosa) listed in policy
    Q5099HCPCS code (Steqeyma) listed in policy
    Q5100HCPCS code (Yesintek) listed in policy
    Q5137HCPCS code (Wezlana) listed in policy history
    Q9996HCPCS code (Pyzchiva) listed in policy history
    Q9998HCPCS code (Selarsdi) listed in policy history
    Q9999HCPCS code (Otulfi) listed in policy history
    Body surface area for moderate-to-severe disease — typical threshold value
    Moderate-to-severe disease BSA threshold>= 10% body surface area (BSA)
    Supported exceptionsExceptions allowed for extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement
    Documentation requiredRecord BSA estimate in clinical notes to support medical necessity
    Weight thresholds for pediatric use — example thresholds for select agents
    Tremfya (guselkumab) pediatric weightWeighs at least 40 kg for individuals aged 6 years or older
    Otezla (apremilast) pediatric weight (oral pediatric formulation)Weighs at least 20 kg (where specified)
    Otezla XR pediatric weightOtezla XR coverage requires at least 50 kg for ages >=6 years
    Body surface area (BSA) — >= 10% (exceptions for special-site disease described)
    Standard BSA threshold>= 10% body surface area (BSA)
    Allowed exceptionsCoverage may be granted despite <10% BSA for extensive recalcitrant facial, pustular hands/feet, or genital involvement
    Clinical requirementHistory of trial and failure of >=1 approved systemic therapy required unless contraindicated
    Icotyde weight — >= 40 kg
    Icotyde weight requirement>= 40 kg
    Icotyde billing noteNew HCPCS code Q5164 added effective July 1, 2026 (policy history)
    Icotyde prior therapyRequires prior systemic therapy and intolerance/failure to specified ustekinumab agents per policy
    Icotyde minimum age — >= 12 years
    Icotyde minimum age>= 12 years
    Icotyde additional requirementAlso requires weighing at least 40 kg and prior therapy per policy
    Prescriber requirementMedication must be prescribed by or in consultation with a dermatologist
    Ustekinumab class minimum age — >= 6 years
    Ustekinumab-class minimum age>= 6 years for indicated ustekinumab agents
    Agent examplesIncludes ustekinumab and biosimilars (Stelara, Imuldosa, Steqeyma, Yesintek, etc.)
    BSA requirement>= 10% BSA (exceptions allowed as described in policy)
    Otezla XR age/weight — >= 6 years and >= 50 kg
    Otezla XR minimum age and weight>= 6 years AND >= 50 kg
    Otezla XR coverage addition2026 update: Otezla XR added to preferred alternatives lists for multiple biologics
    Prior therapy requirementRequires history of adequate trial and treatment failure with >=1 approved systemic therapy unless contraindicated
    Tremfya weight — >= 40 kg
    Tremfya weight threshold>= 40 kg
    Tremfya age requirementUpdated to include individuals aged 6 years or older (policy history)
    BSA requirement>= 10% BSA for plaque psoriasis (exceptions allowed)
    Otezla XR weight threshold — >= 50 kg
    Otezla XR weight threshold>= 50 kg
    Age pairingOtezla XR coverage applies for ages >=6 years when weight >=50 kg
    Policy change noteAdded in 2026 update to prescribing criteria and preferred alternatives lists
    Tremfya weight threshold — >= 40 kg
    Tremfya weight threshold (restated)>= 40 kg
    Age thresholdTremfya indicated for individuals aged 6 years or older per updated criteria
    Requirement contextMust meet prior systemic therapy trial and dermatologist prescribing requirement

    Actions Required by Ordering/Prescribing Providers

    Prior Authorization

    Prior authorization required — demonstrate age, BSA, and prior systemic therapy trial

    Many biologic and systemic psoriasis therapies require prior authorization. Approval generally requires documentation of the patient’s age meeting agent-specific thresholds, disease extent (commonly ≥10% BSA unless an exception applies), and prior trial and inadequate response, intolerance, or contraindication to at least one approved systemic therapy (e.g., methotrexate, cyclosporine, acitretin, or PUVA). Medication must be prescribed by or in consultation with a dermatologist.

    • Document age per agent-specific thresholds (e.g., many biologics ≥6 years; some agents 18+; Tremfya weight requirement updated to ≥40 kg).
    • Document disease extent (commonly ≥10% BSA) or exception criteria (extensive recalcitrant facial, pustular hand/foot, or genital involvement).
    • Document prior trial and failure/intolerance of at least one approved systemic therapy unless contraindicated.
    • Prescriptions must be by or in consultation with a dermatologist.
    Prior Authorization

    Prior authorization plus site-of-service review for biologic/infused agents

    Prior authorization and a site-of-service review are required for listed biologic and infused agents; applicable HCPCS/J-codes and Q-codes are provided in the policy and site-of-service medical necessity rules apply for IV-administered drugs and for individuals aged 13 and older.

    • Site-of-service medical necessity applies to medical benefit reviews and is reviewed for individuals aged 13 and older.
    • IV-administered drugs are subject to site-of-service review and associated HCPCS/J-code listings in the policy.
    Prior Authorization

    Prior authorization must follow medical vs pharmacy benefit routing

    Certain agents are managed under the medical benefit, pharmacy benefit, or both; prior authorization must follow the benefit routing for the specific agent (e.g., infliximab products are medical-benefit managed; many adalimumab and other biologics may be managed through pharmacy and/or medical benefits). Otezla XR coverage routing was added with pediatric age/weight criteria.

    • Confirm whether the requested agent is medical-benefit managed (e.g., Avsola, Inflectra, Remicade, Renflexis) or pharmacy/medical managed per the policy lists.
    • Ensure prior authorization request is submitted to the correct benefit (medical vs pharmacy) to avoid routing denials.
    • Otezla XR was added to preferred alternatives and has coverage for individuals ≥6 years and ≥50 kg.
    Prior Authorization

    Prior authorization required for listed HCPCS/J/Q codes

    Prior authorization is required for specific HCPCS/J/Q codes listed in the policy; requests for drugs represented by those codes must meet the policy’s medical necessity criteria to be approved.

    • Applicable codes include J0139, J1745, J3590, and multiple Q-codes and biosimilar HCPCS codes listed in the coding section.
    • Authorization requests billed under these codes must meet the agent-specific criteria in the policy.
    Step Therapy

    Follow defined step-therapy tiers and document prior failures

    Step therapy tiers are defined and providers must document required prior failures per the step hierarchy; some agents require failure of listed first-line agents before approval for second-line agents.

    • Step tiers include TNF-α antagonists, IL-17 inhibitors, IL-23 inhibitors, TYK2 inhibitors, PDE-4 inhibitors and others.
    • Approval for many second-line agents requires prior inadequate response or intolerance to specified first-line agents as detailed in the policy.
    Prior Authorization

    Document prior inadequate response/intolerance to systemic therapy

    Coverage generally requires documentation of prior inadequate response, intolerance, or contraindication to at least one approved systemic therapy (e.g., methotrexate, cyclosporine, acitretin, or PUVA); for some agents additional specified biologic/oral agent failures are required.

    • Document prior trial(s) and reason for discontinuation (inadequate response, intolerance, or contraindication).
    • Some agents require failure/intolerance of specified biologics or multiple agents (refer to agent-specific sections).
    Note

    Otezla XR added to preferred alternatives — document alternative therapy use

    Otezla XR was added to the list of preferred alternatives for several biologic agents; providers should document use or contraindication of preferred alternatives when step-therapy rules reference them.

    • Otezla XR is now listed as a preferred alternative for Bimzelx, Siliq, Cosentyx, Cimzia, and Ilumya per the 2026 update.
    • If a preferred alternative is tried, document trial dates, dose, and clinical response or intolerance.
    Step Therapy

    Adhere to updated preferred-product sequencing for step therapy

    Providers must follow updated preferred-product sequencing and step requirements; multiple policies revisions updated preferred adalimumab biosimilars and infliximab sequencing that affect authorization prerequisites.

    • Verify member’s formulary and preferred-product lists in the policy history before submitting authorization.
    • Document trials of preferred biosimilars or infliximab products if required by the step sequence.
    Documentation Required

    Submit clinical documentation of diagnosis, BSA, and prior treatments

    Documentation submitted for authorization must support the diagnosis (e.g., chronic plaque psoriasis), BSA involvement, prior trials and failures/intolerance of listed systemic agents, and that the medication is prescribed by or in consultation with a dermatologist.

    • Include documentation of BSA percent or description of special-site disease if <10% (extensive facial, pustular hands/feet, genital involvement).
    • Include medication history noting agents tried, dates, doses, and reasons for discontinuation.
    Documentation Required

    Include office visit notes with authorization request

    Submit office visit notes that contain the diagnosis, relevant history, physical evaluation, and medication history to demonstrate that medical necessity criteria are met.

    • Attach office visit notes showing current disease activity, prior therapies, and clinician rationale for the requested agent.
    Documentation Required

    Provide clinical severity documentation (e.g., GPPGA, BSA) for pustular disease

    Document clinical severity metrics where relevant (trial-defined thresholds such as GPPGA pustulation subscores or BSA) for severe variants like generalized pustular psoriasis; these data are relevant to medical necessity determinations for agents used in pustular disease.

    • For GPP flare requests, document GPPGA pustulation subscore and BSA involvement consistent with trial inclusion (e.g., pustulation subscore ≥2 and ≥5% BSA when applicable).
    • Provide objective severity measures (GPPASI, GPPGA, BSA) when available.
    Documentation Required

    Follow FDA prescribing information and document dosing/monitoring

    Prescribing must follow FDA dosage and administration; policy notes medications are subject to product prescribing information and monitoring requirements and member benefit limitations.

    • Ensure dosing, frequency, and administration route align with FDA-approved prescribing information.
    • Be aware of member-specific benefit limitations or custom formulary exceptions referenced in the policy.
    Billing Rule

    Bill IV-administered drugs through the medical benefit

    Claims for IV-administered drugs described in this policy must be processed through the medical benefit; submitting IV drugs through the pharmacy benefit or incorrect billing route may trigger denial.

    • Submit IV-administered drug claims through the medical benefit only per policy instruction.
    • Verify benefit routing prior to claim submission to avoid billing-route denials.
    Denial Risk

    Site-of-service denials — ensure SOS criteria are met

    Use of a non-preferred or non-medically necessary site of service when the site-of-service criteria are not met is considered not medically necessary and may be denied; initial course hospital-based outpatient infusion is medically necessary for first 90 days when indicated.

    • If site-of-service criteria are not met (e.g., no clinical justification for hospital-based infusion), expect possible denial for site-of-service.
    • Hospital-based outpatient site is considered medically necessary for the initial 90 days for initial course or re-initiation after ≥6 months when criteria are met.
    Denial Risk

    Denial risk if required prior systemic or comparator trials are not documented

    Requests for biologic agents may be denied if required prior trials of approved systemic therapies (e.g., methotrexate, cyclosporine, acitretin, PUVA) or specified comparator biologics are not documented.

    • For many agents, document at least one prior systemic therapy trial unless contraindicated.
    • Some agents require documented failure of specified biologics or multiple agents per agent-specific criteria.
    Denial Risk

    Benefit routing can trigger denials — verify medical vs pharmacy management

    Benefit routing (medical vs pharmacy) affects authorization; requests may be managed under different benefits depending on the agent, and routing to the incorrect benefit could result in denial or delayed approval.

    • Confirm whether the agent is managed through the medical benefit (e.g., infliximab products) or pharmacy/medical benefit before submitting authorization.
    • If routed incorrectly, resubmit to the correct benefit to avoid denial.
    Denial Risk

    Denial triggers — unmet coverage, SOS, or formulary requirements

    Coverage denials commonly occur when coverage criteria, site-of-service medical necessity criteria, or formulary-specific requirements (such as trials of preferred agents or step therapy) are not met; review policy details and member plan exceptions before submission.

    • Check for plan-specific exceptions (custom open/preferred formularies) referenced in policy history and related policies.
    • Document compliance with step-therapy, preferred-product sequencing, and SOS rules to reduce denial risk.

    Background and Safety Evidence

    Psoriasis is a chronic inflammatory skin disease that most commonly presents as plaque psoriasis, characterized by well-demarcated, erythematous, scaly plaques. Pustular forms of psoriasis are much less common but can be more severe and systemic in presentation.

    Definitions and Clinical Terms

    Plaque psoriasis — Psoriasis subtype characterized by red, scaly plaques; described in policy introduction as the common presentation.
    DefinitionPlaque psoriasis: psoriasis subtype characterized by red, scaly plaques; described in the policy introduction as the common presentation
    PrevalenceRepresents about 80% of psoriasis cases
    Clinical noteOften described as well-demarcated erythematous plaques with scaling
    Site of service — Location where a drug is administered (e.g., hospital outpatient, infusion center, physician office, home); site-of-service review applies
    Site of service definitionLocation where a drug is administered (e.g., hospital outpatient, infusion center, physician office, home)
    SOS review applicabilitySite-of-service medical necessity review applies for individuals aged 13 years and older for medical benefit reviews
    Preferred medically necessary sitesPhysician's office, infusion center, home infusion, or hospital-based outpatient setting (first 90 days for initial course)
    Exception (coverage despite <10% BSA) — Coverage may be granted when there is extensive recalcitrant facial involvement, pustular involvement of hands/feet, or genital involvement
    Exception allowing coverage despite <10% BSAMay be granted for extensive recalcitrant facial involvement, pustular involvement of hands/feet, or genital involvement interfering with sexual function
    Clinical impactUsed when localized but functionally or cosmetically significant disease warrants systemic/biologic therapy
    DocumentationProvider must document extent and impact of special-site disease in clinical notes
    Site of service (age threshold) — Site-of-service review is limited to individuals aged 13 years or older for medical necessity determinations relating to administration location
    Age threshold for SOS reviewSite-of-service review is limited to individuals aged 13 years or older
    RationalePediatric IV/infusion administration requires specialized training and equipment; pediatrics differs physiologically and behaviorally from adults
    Exception noteSOS Medical Necessity criteria do NOT apply to Alaska fully-insured members (refer to state-specific rules)
    Plaque psoriasis — Most common form of psoriasis characterized by well-demarcated erythematous plaques with scaling; represents about 80% of cases.
    Plaque psoriasis - conciseMost common form of psoriasis characterized by well-demarcated erythematous plaques with scaling; represents about 80% of cases
    Clinical relevanceOften the initial target for topical therapy; moderate-to-severe disease may require systemic or biologic agents
    Population impactAffects approximately 3.2% of the US population
    Generalized pustular psoriasis (GPP) — A rare subtype characterized by sterile pustules on non-acral skin, may be systemic and life-threatening, with flares often triggered by systemic factors
    GPP definitionGeneralized pustular psoriasis (GPP): rare subtype with sterile pustules on non-acral skin; may be systemic and life‑threatening
    Clinical courseCharacterized by flares that can include systemic symptoms (fever, malaise) and may be triggered by medications or infections
    EpidemiologyGPP comprises ~1% of psoriasis; global prevalence ~1.76 per million
    Palmoplantar pustulosis (PPP) — Persistent pustules on palms/soles, chronic relapsing course, often painful and associated with tobacco use; clinically distinct from GPP.
    PPP definitionPalmoplantar pustulosis (PPP): persistent sterile pustules on palms/soles with chronic relapsing course, often painful
    Distinct featuresClinically distinct from GPP; associated with tobacco use and may have differing genetic associations
    ImpactCan be debilitating despite limited BSA due to location on palms/soles
    DRESS — Drug Reaction with Eosinophilia and Systemic Symptoms noted as an adverse event in spesolimab trials; two cases reported in GPP trial with associated hospitalization.
    DRESS observed with spesolimabDrug Reaction with Eosinophilia and Systemic Symptoms (DRESS) was reported in the GPP trial (two cases) and noted among SAEs
    Severity and outcomesOne RegiSCAR score indicated no DRESS and the other possible DRESS; symptoms resolved without drug treatment; no deaths reported
    Safety implicationMonitoring for DRESS and serious AEs is indicated when using spesolimab for GPP